Drug Impacts, Sensitivity Analyses, and Company Accreditation.

Contents: Section I. Drug Abbreviations. (p. 2) Table A, Drug Abbreviations. Section II. TB Example: How the Impacts of TB Drugs are Calculated. (p. 3) Fig A, Breakdown of TB patient groups. Table B, Impact on TB patient groups for Botswana in 2010. Table C, Disaggregated Drug-Susceptible TB Treatment Regimen. Table D, Possible MDR-TB Treatment Regimens. Table E, MDR-TB Resistance Patterns. Table F, Breakdown of TB Drug Resistance between Different Regimens. Table G, Portion of MDR-TB treatments. Table H, Proportion of Credit Given to Each Drug in Different Treatment Regimens. Table I, XDR-TB Treatment Regimen Drug Proportions. Table J, Disaggregated XDR-TB Treatment Regimens. Section III. HIV Example: How the Impacts of HIV Drugs are Calculated. (p. 11) Table K, Group A and Group B Countries Affected by HIV. Table L, Percentage of People Taking First and Second Line Regimens in Group A Countries. Table M, Antiretroviral Treatment Regimen Proportions and Efficacies for Group A and Group B Countries. Some of the material in this section is reprinted from “Globalization, Global Justice, and Global Health Impact” under a CC BY license, with permission from Public Affairs Quarterly, original copyright 2014 Section IV. Sensitivity Analyses. (p. 18) Fig B, Initial and Secondary Stability for Sensitivity Analyses. Section V. Drug Accreditation between Companies. (p. 25) Table N, Drug Accreditation between Companies. (DOCX)